Kyrexa

Kyrexa is a biotechnology company focused on the discovery and development of novel small molecule therapeutics for neuropsychiatric and neurological disorders. Founded and incubated by Apple Tree Partners (ATP), the company leverages a proprietary platform centered on G protein-coupled receptor (GPCR) biased signaling. Kyrexa's primary research programs target muscarinic receptors, specifically the M1 and M4 subtypes, to provide more effective and better-tolerated treatments for conditions such as schizophrenia and Alzheimer's disease. The company aims to improve patient outcomes by developing highly selective modulators that avoid the side effects associated with traditional GPCR-targeted therapies. By focusing on precision pharmacology within the neuroscience space, Kyrexa seeks to address significant unmet needs in mental health and cognitive decline.